All‐cause mortality
Heparin prophylaxis showed no clear difference in mortality compared with no prophylaxis (moderate certainty).
2 findings from 1 review
Symptomatic VTE
Heparin prophylaxis leads to lower symptomatic VTE compared with no prophylaxis (high certainty).
1 finding from 1 review
Major bleeding
Heparin prophylaxis showed no clear difference in major bleeding compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Minor bleeding
Heparin prophylaxis leads to higher minor bleeding compared with no prophylaxis (high certainty).
1 finding from 1 review
Thrombocytopenia
Heparin prophylaxis showed no clear difference in thrombocytopenia compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Quality of life impairment
1 finding from 1 review
All‐cause mortality (main analysis ‐ active cancer) · patients with cancer with venous thromboembolism
Low molecular weight heparin secondary prophylaxis showed no clear difference in all‐cause mortality (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
All‐cause mortality (time‐to‐event) · patients with cancer with venous thromboembolism
Low molecular weight heparin secondary prophylaxis showed no clear difference in all‐cause mortality (time‐to‐event) compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
Recurrent venous thromboembolism (main analysis ‐ active cancer) · patients with cancer with venous thromboembolism
Low molecular weight heparin secondary prophylaxis probably leads to lower recurrent venous thromboembolism (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (moderate certainty).
1 finding from 1 review
Recurrent venous thromboembolism · patients with cancer with venous thromboembolism
Low molecular weight heparin secondary prophylaxis probably leads to lower recurrent venous thromboembolism (time‐to‐event) compared with vitamin K antagonist secondary prophylaxis (moderate certainty).
1 finding from 1 review
Major bleeding · patients with cancer with venous thromboembolism
Low molecular weight heparin secondary prophylaxis showed no clear difference in major bleeding (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
Minor bleeding (main analysis ‐ active cancer) · patients with cancer with venous thromboembolism
It is very uncertain whether low molecular weight heparin secondary prophylaxis changes minor bleeding (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (very low certainty).
1 finding from 1 review
Thrombocytopenia (main analysis‐ active cancer) · patients with cancer with venous thromboembolism
Low molecular weight heparin secondary prophylaxis showed no clear difference in thrombocytopenia (main analysis‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
Outcomes ( · people with cancer with thrombosis prophylaxis and central venous catheters
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Outcomes ( · people with cancer with thrombosis prophylaxis and central venous catheters
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
Low‐molecular‐weight heparin (LMWH) showed no clear difference in all‐cause mortality (up to 3 months) compared with vitamin K antagonist (VKA) (low certainty).
1 finding from 1 review
Symptomatic catheter‐related thrombosis (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes symptomatic catheter‐related thrombosis (up to 3 months) compared with vitamin K antagonist (VKA) (very low certainty).
1 finding from 1 review
All‐cause mortality (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
Low‐molecular‐weight heparin (LMWH) showed no clear difference in all‐cause mortality (up to 3 months) compared with no LMWH (low certainty).
1 finding from 1 review
Symptomatic catheter‐related thrombosis measured as asymptomatic catheter‐related thrombosis (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes symptomatic catheter‐related thrombosis measured as asymptomatic… compared with vitamin K antagonist (VKA) (very low certainty).
1 finding from 1 review
Pulmonary embolism · people with cancer with thrombosis prophylaxis and central venous catheters
Low‐molecular‐weight heparin (LMWH) showed no clear difference in pulmonary embolism (up to 3 months) compared with vitamin K antagonist (VKA) (low certainty).
1 finding from 1 review